Multikinase inhibitors in thyroid cancer

被引：10

作者：

Licitra, Lisa ^{[1
]}

Locati, Laura D. ^{[1
]}

Greco, Angela ^{[2
]}

Granata, Roberta ^{[1
]}

Bossi, P. ^{[1
]}

机构：

[1] Ist Nazl Tumori, Fdn IRCCS, Head & Neck Canc Med Oncol Unit, I-20133 Milan, Italy

[2] Ist Nazl Tumori, Fdn IRCCS, Dept Expt Oncol & Mol Med, Mol Mech Unit, I-20133 Milan, Italy

来源：

EUROPEAN JOURNAL OF CANCER | 2010年 / 46卷 / 06期

关键词：

Thyroid cancer; Multikinase inhibitors; ENDOTHELIAL GROWTH-FACTOR; PHASE-II TRIAL; BRAF MUTATION; RESPONSE EVALUATION; IMATINIB MESYLATE; SIGNALING PATHWAY; FACTOR EXPRESSION; HIGH PREVALENCE; SOLID TUMORS; CARCINOMA;

D O I：

10.1016/j.ejca.2010.01.010

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Biological agents are rapidly developing for the treatment of metastatic RAI resistant thyroid cancer. The most promising results were shown by agents that target BRAF and VEGFR rather than RET. BRAF V600E mutation seems to be positively associated with tumour response by using BRAF targeting agents. With these agents impressive clinical responses and prolonged disease stabilisation were observed. This activity compares favourably with that of chemotherapy with less prominent toxicity, although typically associated drug side-effects should be promptly recognised and managed. To date no drug has proved to prolong survival, as such none of these agents has been approved. (C) 2010 Elsevier Ltd. All rights reserved.

引用

页码：1012 / 1018

页数：7

共 50 条

[1] Multikinase inhibitors in thyroid cancer
Licitra, Lisa
Locati, Laura D.
ANNALS OF ONCOLOGY, 2012, 23 : 328 - 333
[2] Effects and Role of Multikinase Inhibitors in Thyroid Cancer
Laursen, Rasmus
Wehland, Markus
Kopp, Sascha
Pietsch, Jessica
Infanger, Manfred
Grosse, Jirka
Grimm, Daniela
CURRENT PHARMACEUTICAL DESIGN, 2016, 22 (39) : 5915 - 5926
[3] Multikinase inhibitors: a new option for the treatment of thyroid cancer
Gild, Matti L.
Bullock, Martyn
Robinson, Bruce G.
Clifton-Bligh, Roderick
NATURE REVIEWS ENDOCRINOLOGY, 2011, 7 (10) : 617 - 624
[4] Multikinase inhibitors: a new option for the treatment of thyroid cancer
Matti L. Gild
Martyn Bullock
Bruce G. Robinson
Roderick Clifton-Bligh
Nature Reviews Endocrinology, 2011, 7 : 617 - 624
[5] Emerging role of multikinase inhibitors for refractory thyroid cancer
Perez, Cesar A.
Arango, Belisario A.
Velez, Michel
Raez, Luis E.
Santos, Edgardo S.
BIOLOGICS-TARGETS & THERAPY, 2012, 6 : 257 - 265
[6] Multikinase inhibitors in thyroid cancer: timing of targeted therapy
Matti L. Gild
Venessa H. M. Tsang
Roderick J. Clifton-Bligh
Bruce G. Robinson
Nature Reviews Endocrinology, 2021, 17 : 225 - 234
[7] Multikinase inhibitors in thyroid cancer: timing of targeted therapy
Gild, Matti L.
Tsang, Venessa H. M.
Clifton-Bligh, Roderick J.
Robinson, Bruce G.
NATURE REVIEWS ENDOCRINOLOGY, 2021, 17 (04) : 225 - 234
[8] Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib
Stjepanovic, Neda
Capdevila, Jaume
BIOLOGICS-TARGETS & THERAPY, 2014, 8 : 129 - 139
[9] Use of multikinase inhibitors/lenvatinib in singular thyroid cancer scenarios
Zafon, Carles
Castelo, Beatriz
CANCER MEDICINE, 2022, 11 : 3 - 4
[10] Emerging multikinase inhibitors for the treatment of differentiated thyroid cancer: whom to treat?
Krajewska, Jolanta
Rusinek, Dagmara
Jarzab, Barbara
TRANSLATIONAL CANCER RESEARCH, 2016, 5 : S1340 - S1344

← 1 2 3 4 5 →